Abstract 29P
Background
Immune checkpoint inhibitors (ICI) will become the new standard therapy for early muscle-invasive bladder cancer (MIBC). Despite high response rates, a significant proportion of patients still dies from lethal relapse. Moreover, validated biomarkers to ICI are lacking. Here, we evaluated systemic inflammatory index (SII) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers for MIBC patients in the AURA trial.
Methods
AURA is a prospective phase 2 trial (NCT03674424) evaluating neoadjuvant avelumab alone or in combination with different chemotherapy regimens according to cisplatin eligibility. Pre-treatment SII, deriving from the formula (neutrophils x platelets)/lymphocytes, and baseline PLR, absolute platelets to lymphocytes ratio, were categorized as low < median or high ≥ median. Associations of biomarkers with pathological responses, event-free survival (EFS) and overall survival (OS) were measured using Fisher’s exact test, Kaplan-Meier and Cox regression methods.
Results
Low SII showed a significant correlation (p=0.002) with pathological complete response (pCR), longer EFS (median: NR vs 26 months, HR = 0.42) and longer OS (median: NR vs 40 months, HR = 0.50) and a trend for downstaging ( Low pre-treatment SII, witnessing low level of systemic inflammation, was significantly associated with response to neoadjuvant chemo-immunotherapy as well as with longer survival, suggesting that SII could be used as a predictive biomarker for MIBC treatment tailoring, if further validated. In contrast, baseline low PLR was not correlated with better outcomes, suggesting that the platelet count alone is not strong enough to reflect the systemic inflammation. NCT03674424. Institut Jules Bordet and FNRS. Merck KGaA, Darmstadt, Germany. J. Blanc: Financial Interests, Institutional, Advisory Role: Merck; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Personal, Other, Travel support: Ipsen, AstraZeneca, Merck. N. Martinez Chanza: Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck. A. Carnot: Financial Interests, Personal, Advisory Board: MSD Oncology, Janssen Oncology; Financial Interests, Personal, Invited Speaker: Astellas Pharma. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca. C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Seattle Genetics, Amgen, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Personal, Other, Travel: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences; Financial Interests, Personal, Invited Speaker: Prime Oncology; Financial Interests, Personal, Advisory Board, Stock options: Signatur Biosciences; Financial Interests, Personal, Stocks/Shares, Stock: Signatur Biosciences. All other authors have declared no conflicts of interest.Conclusions
Clinical trial identification
Legal entity responsible for the study
Funding
Disclosure
Resources from the same session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract